“Through due diligence, investors and pharma companies take a closer look at their potential partner, the asset, and the deal itself to validate claims and evaluate risks. With many millions of dollars riding on the success of licensing and acquisition activities, a deal gone wrong can mean significant debt and …

"After being introduced to this company [who requested to remain anonymous] through IN-PART, initial conversations indicated that this was a technology they were very much interested in investigating further. They signed an NDA and MTA, which followed further conversations about what the company wished to gain from the testing of …